Exploring Analysis Approaches for Using the Dopamine Transporter Striatal Binding Ratio in Early- to Mid-Stage Parkinson's Disease Modification Trials.
探索在早期至中期帕金森病修飾試驗中使用多巴胺轉運蛋白紋狀體結合比率的分析方法。
Mov Disord Clin Pract 2024-08-22
PT320, a Sustained-Release GLP-1 Receptor Agonist, Ameliorates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson's Disease.
PT320,一種持續釋放的GLP-1受體激動劑,在帕金森氏病小鼠模型中改善L-DOPA誘導的運動障礙。
Int J Mol Sci 2023-04-11
DPP-4 inhibitors sitagliptin and PF-00734,200 mitigate dopaminergic neurodegeneration, neuroinflammation and behavioral impairment in the rat 6-OHDA model of Parkinson's disease.
DPP-4 抑制劑 sitagliptin 和 PF-00734,200 在大鼠 6-OHDA 帕金森氏症模型中緩解多巴胺能神經退化、神經炎症和行為障礙。
Geroscience 2024-04-02
Sodium-glucose cotransporter 2 inhibitors and the risk of Parkinson disease in real-world patients with type 2 diabetes.
鈉-葡萄糖共轉運蛋白 2 抑制劑與實際世界中 2 型糖尿病患者罹患帕金森病的風險。
Diabetes Obes Metab 2024-09-11
Anti-diabetic drug use and reduced risk of Parkinson's disease: A community-based cohort study.
抗糖尿病藥物使用與帕金森病風險降低:一項社區基礎的隊列研究。
Parkinsonism Relat Disord 2024-09-11
SGLT2 Inhibitor Use and Risk of Dementia and Parkinson Disease Among Patients With Type 2 Diabetes.
SGLT2 抑制劑使用與 2 型糖尿病患者罹患癡呆症和帕金森病的風險。
Neurology 2024-09-18